Category:

Comstock Inc. (LODE) – Collaborative Agreements with the Department of Energy’s National Renewable Energy Laboratory

Posted on by cpereira@noblefcm.com


Thursday, October 03, 2024

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Laying the groundwork for a successful moonshot. Comstock IP Holdings, a wholly owned subsidiary, executed an Exclusive License Agreement (ELA) and Cooperative Research and Development Agreement (CRADA) with the Alliance for Sustainable Energy, the managing and operating contractor of the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL). The agreements provide access to technologies developed by NREL and the Massachusetts Institute of Technology (MIT) to convert lignocellulosic biomass into aromatic sustainable aviation fuel (SAF). The goal is to produce the world’s first 100% renewable SAF at costs approaching parity with fossil fuels by integrating Comstock and NREL technologies.

Cooperative Research and Development Agreement. Terms include a three-year scope of work to jointly develop an integrated process based on Comstock and NREL processes and technologies to refine woody biomass into aromatic SAF and other renewable fuels. Comstock will fund the research and contribute staff, equipment, and use of its pilot facility in Wisconsin. The CRADA is expected to result in the construction of a pre-commercial pilot system to affirm requirements needed to scale-up and incorporate the resulting process into Comstock’s planned 50,000 metric ton per year commercial demonstration facility.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Dockworkers Strike Over Automation is Just the Beginning: What It Means for Labor and Tech

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Dockworkers strike over pay and automation concerns, signaling rising labor tensions over technology.
– Labor unions across various industries are pushing back against job displacement due to automation.
– Experts predict the effects of automation will soon impact all sectors, not just manual labor jobs.

The ongoing dockworkers’ strike over demands for higher wages and a ban on automation marks the latest battle in the growing resistance to technology in the workplace. As automation and artificial intelligence (AI) continue to reshape industries, labor unions across the U.S. are beginning to take a stand, seeking to control how these advancements impact their livelihoods. Rather than allowing employers to dictate the changes, workers are pushing for a more equitable approach to technological progress, one that balances innovation with job security.

The dockworkers’ strike is part of a broader trend that has seen unions across various industries, from Hollywood writers to auto workers, rally against automation and AI’s encroachment on their jobs. In recent months, employees have walked off the job, demanding fairer working conditions and stronger protections against the displacement caused by these emerging technologies. These collective actions are not just about wages; they represent a broader anxiety about the future of work in an increasingly automated world.

“These labor movements are connected by a common thread of resistance to technology and automation,” says Alexander Hertel-Fernandez, an associate professor at Columbia University. “As unions begin to succeed in one sector, it builds momentum and encourages workers in other fields to push back as well.”

One of the primary concerns of the dockworkers is that automation could lead to massive job losses. The shipping industry, which traditionally relies heavily on human labor, is now seeing advancements in robotics and AI that threaten to replace workers with machines. If automation is fully implemented in ports, it could transform an industry once dominated by human labor into one driven by robotics. This shift raises fears about the future of jobs in the sector and the potential consequences for workers who may find themselves obsolete.

The effects of a prolonged strike are already being felt, with delays in cargo shipments, higher prices, and supply chain disruptions on the horizon. Critics of the strike argue that resisting automation is akin to fighting the tide of progress. However, labor advocates counter that the conversation should be less about resisting technology and more about ensuring that workers are not left behind in the process.

“We need to strike a balance between advancing technology and protecting workers’ livelihoods,” says Darrell West, a senior fellow at the Brookings Institution. West suggests that retraining programs for displaced workers could offer a potential solution. “Mandating retraining programs for employees affected by automation could allow them to transition into other roles within the company or industry, rather than simply being pushed out.”

While automation may currently be impacting sectors like shipping and manufacturing, its reach is expanding. West warns, “Eventually, this will happen across all industries.” Whether it’s manual labor or white-collar jobs, no one is immune from the disruptions caused by technological advancements. What we see with the dockworkers today could set a precedent for how other sectors respond when automation begins to threaten their jobs.

Ultimately, the dockworkers’ strike is not just about protecting jobs in the shipping industry—it’s about establishing a framework for how society handles the rapid rise of technology. The decisions made in this strike could shape the future of work for employees across various industries, many of whom are also at risk of displacement by automation.

OpenAI Secures $6.5 Billion in Funding, Valued at Over $150 Billion

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– OpenAI closes a $6.5 billion funding round, valuing the company at over $150 billion.
– Thrive Capital led the investment, with participation from other global investors.
– OpenAI solidifies its position as one of the largest venture-backed startups alongside SpaceX and ByteDance.

OpenAI has successfully raised over $6.5 billion in new funding, placing the artificial intelligence company at a staggering $150 billion valuation. This major deal, one of the largest private investments in tech history, further cements OpenAI’s dominance in the rapidly growing AI sector, alongside other tech giants like Elon Musk’s SpaceX and TikTok’s parent company, ByteDance.

The funding round, spearheaded by Thrive Capital, the venture firm headed by Josh Kushner, attracted significant interest from global investors, reflecting the industry’s confidence in AI’s transformative potential. OpenAI’s latest financial boost comes amid increased competition in the development of generative AI technologies. With this capital infusion, the company is well-positioned to further innovate and expand its technological capabilities.

This investment also highlights the industry’s willingness to back costly AI research, which powers advancements in generative AI. As the technology behind AI becomes increasingly expensive and complex, OpenAI’s ability to attract such high levels of funding showcases its pivotal role in shaping the future of artificial intelligence.

OpenAI’s recent funding round follows a turbulent year for the company. In November of last year, the company’s board made the surprising decision to fire and then quickly reinstate Chief Executive Officer Sam Altman. Despite the internal shake-up, including the loss of key leaders like Chief Technology Officer Mira Murati and Sutskever, OpenAI has remained a dominant force in the AI space. It has revamped its board and expanded its team, hiring hundreds of new employees to strengthen its foundation.

Thrive Capital’s role in leading the funding round is a testament to the venture capital firm’s belief in AI’s potential to revolutionize industries. OpenAI’s continued growth and its hefty valuation reinforce the broader tech sector’s commitment to pushing the boundaries of AI research, development, and application.

Release – ISG Sells Its Automation Unit to UST

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on III

Move sharpens ISG’s focus, strengthens balance sheet and immediately enhances shareholder value

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group ( ISG ) (Nasdaq: III ), a leading global technology research and advisory firm, said today it has sold its automation unit to UST, a leading digital transformation solutions company, for $27 million in an all-cash transaction, with a portion of the proceeds placed in escrow, to be released contingent upon meeting certain conditions.

The unit offers robotic process automation (RPA) software implementation and licensing services. It was established as a startup business in 2017 to meet the emerging demand for RPA.

ISG Chairman and CEO Michael P. Connors said the sale is a “win-win” for both ISG and UST.

“With this sale, ISG emerges as a stronger, more focused firm, devoted to serving our clients by leveraging our towering strengths in sourcing, powered by our AI-driven ISG Tango™ platform; digital transformation, including enterprise change and training-as-a-service; AI advisory, technology research and supplier governance,” Connors said. “In addition, the cash proceeds of the sale immediately strengthen our balance sheet and improve shareholder value.

“At the same time, our former automation unit will benefit from being part of a larger technology services organization in UST, one that we have known and respected for years, with the resources and scale to compete in the intelligent automation space,” Connors said.

Commenting on UST’s acquisition, Sajesh Gopinath, general manager and go-to-market leader, UST SmartOps, said: “This strategic investment in the intelligent automation space solidifies UST’s position as a market leader in a dynamic sector that has the potential to transform industries, enhance productivity, improve customer experiences, and generate new revenue streams. By onboarding experienced intelligent automation consultants and capabilities, UST is strengthening its standing in a competitive market and broadening its partner ecosystem to position itself for future growth and meet the emerging needs of our clients.”

Connors said ISG decided to exit the business because its implementation and software licensing activities no longer were a strategic fit with ISG’s position as an independent, third-party advisory firm.

ISG received $20 million in cash at closing with the remaining $7 million held in escrow. Of this amount, $4 million is to be released from escrow over the next 90 days as certain contractual conditions with clients are met, and the remaining $3 million is to be released after the end of the first quarter of 2025, based on the achievement of certain revenue targets. Net proceeds from the transaction are expected to provide the opportunity to reduce debt and return capital to shareholders.

To reflect the impact of the divestiture activity, ISG said it is updating its third-quarter guidance, targeting revenues in the range of $60 million to $61 million, and adjusted EBITDA (a non-GAAP measure defined below under “Non-GAAP Financial Measures”) in the range of $6.5 million to $7.0 million.

Sett & Lucas served as financial advisor to ISG, and Katten Muchin Rosenman LLP served as legal advisor.

ISG will file a Form 8-K with the Securities and Exchange Commission in connection with the sale.

Conference Call

ISG will hold a conference call today, Wednesday, October 2, at 4:30 p.m., US ET, to discuss the transaction. The call can be accessed by dialing (800) 715-9871 , or, for international callers, by dialing +1 (646) 307-1963 . The access code is 3455640 . A recording of the call will be available on ISG’s investor relations page for approximately four weeks following the call.

Forward-Looking Statements

This communication contains “forward-looking statements” which represent the current expectations and beliefs of management of ISG concerning future events and their potential effects. Statements contained herein including words such as “anticipate,” “believe,” “contemplate,” “plan,” “estimate,” “target,” “expect,” “intend,” “will,” “continue,” “should,” “may,” and other similar expressions are “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future results and are subject to certain risks and uncertainties, many of which are beyond the control of ISG, its directors and its management, that could cause actual results to differ materially from those anticipated, including, without limitation: (1) the occurrence of any event, change or other circumstance that could affect ISG’s rights or obligations under the Share Purchase Agreement governing the divestiture, (2) risks related to the disruption of management’s attention from ISG’s ongoing business operations due to the divestiture and ISG’s obligations under the Share Purchase Agreement, (3) risks that the divestiture may disrupt current plans and operations and any potential difficulties in employee retention as a result and (4) the effect of the announcement of the transaction on the ISG’s relationships with its customers and suppliers and on its business generally. Certain of these and other applicable risks, cautionary statements and factors that could cause actual results to differ from ISG’s forward-looking statements are included in ISG’s filings with the U.S. Securities and Exchange Commission. ISG undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

Non-GAAP Financial Measures

ISG reports all financial information required in accordance with U.S. generally accepted accounting principles (GAAP). In its updated third-quarter guidance appearing in this release, ISG has presented both GAAP financial results as well as non-GAAP information. ISG believes that evaluating its ongoing operating results will be enhanced if it discloses certain non-GAAP information. These non-GAAP financial measures exclude non-cash and certain other special charges that many investors believe may obscure the user’s overall understanding of ISG’s current financial performance and the Company’s prospects for the future. ISG believes that these non-GAAP measures provide useful information to investors because they improve the comparability of the financial results between periods and provide for greater transparency of key measures used to evaluate the Company’s performance.

In this press release, ISG provides adjusted EBITDA (defined as net income, plus interest, taxes, depreciation and amortization, foreign currency transaction gains/losses, non-cash stock compensation, interest accretion associated with contingent consideration, acquisition-related costs, and severance, integration and other expense), which is a non-GAAP measure that the Company believes provide useful information to both management and investors by excluding certain expenses, which management believes are not indicative of ISG’s core operations. This non-GAAP measure is used by ISG to evaluate the Company’s business strategies and management’s performance.

Management believes this information facilitates comparison of underlying results over time. Non-GAAP financial measures, when presented, are reconciled to the most closely applicable GAAP measure. Non-GAAP measures are provided as additional information and should not be considered in isolation or as a substitute for results prepared in accordance with GAAP. A reconciliation of the forward-looking non-GAAP estimates contained herein to the corresponding GAAP measures is not being provided, due to the unreasonable efforts required to prepare it.

About UST

Since 1999, UST has worked side by side with the world’s best companies to make a powerful impact through transformation. Powered by technology, inspired by people, and led by our purpose, we partner with our clients from design to operation. Our digital solutions, proprietary platforms, engineering expertise, and innovation ecosystem turn core challenges into impactful, disruptive solutions. With deep industry knowledge and a future-ready mindset, we infuse innovation and agility into our clients’ organizations—delivering measurable value and positive lasting change for them, their customers, and communities around the world. Together, with 30,000+ employees in 30+ countries, we build for boundless impact—touching billions of lives in the process. Visit us at www.UST.com .

About ISG

ISG (Information Services Group) (Nasdaq: III ) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including AI, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com .

Source: Information Services Group, Inc.

Release – LODE: Execution of Exclusive License and Cooperative R&D Agreement with Department of Energy’s National Renewable Energy Laboratory

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on LODE

World Class Innovation Team Set Sights on 100% Renewable Sustainable Aviation Fuel and Fossil Parity

VIRGINIA CITY, NEVADA, October 2, 2024 – Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced the execution by Comstock’s wholly-owned subsidiary, Comstock IP Holdings LLC, of an Exclusive License Agreement (“ELA”) and Cooperative Research and Development Agreement (“CRADA”) with Alliance for Sustainable Energy LLC (“Alliance”), the managing and operating contractor of the U.S. Department of Energy’s (“DOE”) National Renewable Energy Laboratory (“NREL”), involving technologies developed by NREL and the Massachusetts Institute of Technology (“MIT”) for conversion of lignocellulosic biomass into aromatic sustainable aviation fuel (“SAF”). NREL and MIT are separately party to an Inter-Institutional Agreement that appointed NREL the exclusive right to license NREL’s and MIT’s joint intellectual properties, and Comstock IP Holdings previously granted Comstock Fuels Corporation the master exclusive rights for commercialization of its existing and new renewable fuels technologies.

Comstock’s Existing Process

Comstock Fuels offers advanced lignocellulosic biomass refining solutions that produce market-leading yields of cellulosic ethanol, gasoline, renewable diesel, SAF, and other renewable fuels at extremely low carbon intensities. The Comstock Fuels process generally involves: (1) solvolytic digestion and fractionation of lignocellulosic biomass, (2) bioconversion of cellulose into Cellulosic Ethanol, (3) esterification of lignin and other derivatives into Bioleum Oil, (4) hydrodeoxygenation of Bioleum Oil into Hydrodeoxygenated Bioleum Oil (“HBO”), (5) refining of the resulting intermediates into ASTM compliant renewable fuels, and (6) gas-to-liquids emissions capture and fuel conversion. The first five of these processes are proven to produce up to 125 gallons of renewable fuel per dry metric ton of feedstock (on a gasoline gallon equivalent basis, or GGE), depending on feedstock, lignin content, site conditions, and other process parameters, with extremely low carbon intensity scores of 15. The sixth step has the potential to increase bulk biomass conversion yields even further, to more than 140 GGE and more than 70% of the theoretical maximum yield from most forms of woody biomass.

Integrated Process

Comstock IP Holdings is focused on continuously improving the proven performance and operations of Comstock Fuel’s commercial refining solutions, including by increasing feedstock diversity, bulk conversion yields, and product quality for use in SAF while decreasing total variable costs.

The technologies covered by the NREL license have the proven potential to contribute to each of those objectives, including by depolymerizing and stabilizing intermediates, by reforming feedstock derived water to decrease reliance on fossil hydrogen, and by removing oxygen in a way that favors high concentrations of aromatic hydrocarbons for use in SAF.

David Winsness, President of Comstock Fuels, said, “Our existing commercial process unlocks and converts wasted, unused, and purpose grown woody biomass into renewable fuels at extraordinary yields and carbon intensities, essentially creating an endless oilwell hidden in plain sight. Our planned commercial facilities have been designed to tap into that oilwell to produce an array of intermediates and fuels. However, further developing and integrating the NREL technologies into our process could give us the remarkable additional ability to maximize aromatic content and quality specifically for high value use in addressing the recent global surge in demand for SAF.”

World Class Team

The terms of the CRADA involve a three-year scope of work to jointly develop an integrated process based on Comstock’s existing process and the NREL technologies for the solvocatalytic refining of woody biomass into aromatic SAF and other renewable fuels. Comstock will fund the research and contribute staff, equipment, and use of its pilot facility in Wisconsin. The joint work will be supported by a world class team, including Gregg Beckham, David Brandner, Mickey Stone, and Michelle Reed of NREL, Yuriy Román-Leshkov, MIT’s Robert T. Haslam Professor in Chemical Engineering, and Joshua Heyne, Director of the Bioproducts, Sciences, and Engineering Lab at Washington State University. The CRADA is anticipated to culminate in construction of a pre-commercial pilot system to validate the requirements needed to rapidly scale-up the resulting process into Comstock’s already planned 50,000 metric ton per year commercial demonstration facility.

Gregg Beckham, Senior Research Fellow for NREL, said, “An integrated process based on Comstock’s and NREL’s technologies would have remarkable potential in decarbonizing liquid fuels. Comstock’s established market leadership and commercial scale-up plans for its existing process provide an exciting opportunity to accelerate commercialization of NREL’s technology. Our respective teams from NREL and MIT are delighted to work with Comstock to scale-up this technology for low-carbon fuels and products.”

“Comstock’s mission is to enable systemic decarbonization, starting with transportation,” said Kevin Kreisler, Comstock’s chief technology officer. “Our plan to do so involves developing and commercializing highly profitable new processes that bootstrap the Earth’s natural carbon cycle while enabling stakeholders at all levels of the mobility supply chain to produce and use enough renewable fuels to decarbonize at globally meaningful scales. Our existing commercial process launches that effort, but we believe that we can maximize the breadth and rate of global market adoption with continued innovation to produce the world’s first 100% renewable SAF at costs that approach parity with fossil fuels. We believe that feat to be achievable by integrating Comstock’s and NREL’s technologies, and we’re excited to get to work.”

The ELA provides Comstock IP Holdings with the exclusive worldwide right to use the NREL technologies in the processing and conversion of seed plants to renewable fuels and renewable fuel feedstocks, including native, hybrid, and transgenic phenotypes, and derivatives thereof, excluding switchgrass, big bluestem, miscanthus, and the leaves, stalks, and husks produced during the harvesting of corn, subject to limited geographic restrictions, in exchange for royalty and other fees linked to sales of licensed products and sublicensing.

NREL’s and MIT’s prior work on the NREL technologies was initially funded by the Center for Bioenergy Innovation, a DOE Research Center supported by the Office of Biological and Environmental Research in the DOE Office of Science, and the DOE Bioenergy Technologies Office on the Lignin Conversion to Sustainable Aviation Fuel Blendstocks project. More information on the technologies is available online in the articles titled Catalytic Process With Lignin Could Enable 100% Sustainable Aviation Fuel, Making Aviation Fuel from Biomass, and Continuous Hydrodeoxygenation of Lignin to Jet-Range Aromatic Hydrocarbons.

Technology Readiness Level

Comstock uses the technology readiness scale to estimate the readiness of technology from conception to commercialization, iterating sequentially as follows: (i) TRL 1 (basic principles observed and reported); (ii) TRL 2 (technology concept and application formulated); (iii) TRL 3 (analytical and experimental proof of concept); (iv) TRL 4 (validation in laboratory environment); (v) TRL 5 (pre-pilot scale validation in relevant environment); (vi) TRL 6 (pilot prototype demonstration in relevant environment); (vii) TRL 7 (scaled-up commercial prototype in operational environment); (viii) TRL 8 (commercial system demonstration); (ix) TRL 9 (commercial maturity).

The NREL technologies covered by the Comstock license have been validated at TRL 4. The scope of work under the CRADA involves rapid validation of an integrated TRL 3 process based on Comstock’s and NREL’s technologies, followed by construction of a TRL 6 pre-commercial pilot system. Once complete, a modular TRL 7 scale-up of the integrated process would be added to Comstock’s recently announced 50,000 metric ton per year demonstration facility to provide the data required for scale-up in Comstock’s planned 1,000,000 metric ton per year commercial facilities at TRL 8.

About Comstock Inc.

Comstock Inc. (NYSE: LODE) commercializes innovative technologies that contribute to global decarbonization and the clean energy transition by efficiently converting under-utilized natural resources, primarily, woody biomass into low-carbon renewable fuels, end-of-life metal extraction and renewal, and generative AI-enabled advanced materials synthesis and mineral discovery for sustainable mining. To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its Twitter, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

CONTACTS:

For investor inquiries:
RB Milestone Group LLC
Tel (203) 487-2759
ir@comstockinc.com

For media inquiries or questions:
Comstock Inc., Zach Spencer
Tel (775) 847-7532
questions@comstockinc.com

Forward Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Release – PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Posted on by aweinsoff@channelchek.com

Research News and Market Data on PDSB

100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)
88% (15/17) of patients had a complete metabolic response
IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024

PRINCETON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that updated data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune® HPV (formerly PDS0101) with chemoradiation to treat locally advanced cervical cancer were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2024 in an oral presentation by Adam Grippin, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center. The abstract was granted Basic/Translational Science Award from the ASTRO Annual Meeting Steering Committee.

“HPV is responsible for virtually all cervical cancers and presents an opportunity for immunologic targeting1. However, there are currently no FDA-approved HPV-targeted immunotherapies to treat cervical cancer,” said Ann Klopp, M.D., Ph.D., Professor of Radiation Oncology and Head of the Gynecologic Section at MD Anderson. “These data suggest that further investigation is warranted into the safety and efficacy of Versamune® HPV in combination with standard of care in the treatment of locally advanced cervical cancer.”

The IMMUNOCERV Phase 2 clinical trial (NCT04580771) evaluated the efficacy, safety and tolerability of Versamune® HPV in combination with standard-of-care chemoradiotherapy for the treatment of locally advanced cervical cancer. The investigator-initiated study enrolled 17 newly diagnosed high-risk patients with large tumors of at least 5 cm in size. Highlights from the presentation include:

  • All patients received at least 2 doses of Versamune® HPV.
  • Median follow-up was 19 months.
  • 36-month overall survival (OS) rate was 84.4%, and 100% for the eight patients who received all five doses of Versamune® HPV. Historical published data show 36-month OS rate with chemoradiation in this population of approximately 64%.2
  • 36-month progression free survival (PFS) rate was 74.9%, among all patients and 100% for the eight patients who received all five doses of Versamune® HPV. Historical published data show 36-month PFS rate with chemoradiation in this population of approximately 61%.2
  • Complete metabolic response (CMR) was achieved in 15/17 (88%) patients.
  • Versamune® HPV appeared to be safe and well-tolerated. The most common treatment-related toxicities were injection site reactions in twelve patients (71%).

“We are pleased that data from the Phase 2 IMMUNOCERV trial demonstrate compelling clinical activity and a promising safety profile,” said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech. “Based on our continued research in various HPV-positive cancers, Versamune® HPV appears to work in combination with a variety of therapeutic agents to generate clinical responses and promote improved survival in patients with minimal toxicity. We look forward to the next steps in the development of Versamune® HPV for locally advanced cervical cancer.”

  1. National Cancer Institute, Cervical Cancer Causes, Risk Factors and Prevention. https://www.cancer.gov/types/cervical/causes-risk-prevention
  2. Rose PG, et al. Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer. N Engl J Med. 1999;340:1144-53.

About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

For more information, please visit www.pdsbiotech.com.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS01ADC, Versamune® HPV (formerly PDS0101), PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS01ADC, Versamune® HPV, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email: jmccargo@6degreespr.com

Great Lakes Dredge and Dock Secures $342 Million in New Dredging Contracts

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Great Lakes Dredge & Dock (GLDD) wins $342.3 million in new dredging contracts, enhancing its revenue visibility.
– GLDD also has $350 million in low bids and options, with a potential project pipeline exceeding $1.5 billion.
– The largest project, Sabine-Neches Waterway Channel Improvement, is valued at $219.1 million and begins in 2025.

Great Lakes Dredge & Dock Corporation (GLDD) has announced significant project wins, receiving $342.3 million in new dredging contracts. These latest awards are expected to further strengthen the company’s revenue visibility and enhance its already sizable project backlog, positioning GLDD for long-term growth in the highly competitive dredging sector.

Among the awarded projects is the Sabine-Neches Waterway Channel Improvement, Contract 6 Project in Texas, the largest of the contracts valued at $219.1 million. This project will commence in mid-2025 and is anticipated to complete by late 2026. Additionally, the company secured several other projects, including the Canaveral Harbor Sand Bypass Project in Florida, the Absecon Island Beach Renourishment Project in New Jersey, and others in Texas and Massachusetts.

In addition to the new awards, GLDD has approximately $350 million in low bids and pending options, bringing its total potential pipeline to more than $1.5 billion. The company highlighted that these ongoing project wins align with its strategy of solidifying its market leadership in the U.S. dredging industry. GLDD’s consistent ability to secure new projects not only reflects its strong bidding capacity but also signals sustained demand for dredging services across the U.S. coastlines and waterways.

Long-Term Outlook and Market Leadership

GLDD is the largest provider of dredging services in the United States and has successfully built a reputation for strong project execution, high equipment utilization, and solid operational performance. With a current dredging backlog of $807.9 million as of the second quarter of 2024, the company is well-positioned to bid on future projects and maintain a robust pipeline. The newly awarded contracts will further boost the company’s project visibility, ensuring continued growth through 2026.

The projects GLDD has secured cover a range of services, from beach renourishment to channel improvements, all of which are critical to maintaining the U.S. coastline, protecting natural resources, and facilitating safe and efficient maritime trade. With the Federal Reserve’s recent interest rate cuts, GLDD anticipates a positive market environment, supporting its long-term strategy of continued growth in the heavy construction and dredging sectors.

Strong Market Performance

In the past three months, GLDD’s stock has surged 35%, outperforming the broader heavy construction sector, which has grown by 16.2%. The company’s stock growth reflects strong investor confidence in its ability to continue winning contracts, which are crucial for revenue generation and building a strong backlog. With ongoing cost-reduction initiatives, increased equipment utilization, and a diversified project portfolio, GLDD is positioned for solid performance in the years ahead.

The company’s proactive approach to securing contracts, coupled with strong execution, continues to drive its market leadership. With market conditions expected to remain robust through 2026, GLDD’s outlook remains positive.

Watch our exclusive interview with Great Lakes Dredge & Dock (GLDD) CEO, CFO & SVP of Offshore Wind

Resources Connection (RGP) – First Look 1Q25 – Environment Remains Challenging but Green Shoots Evident

Posted on by cpereira@noblefcm.com


Wednesday, October 02, 2024

Resources Connection, Inc. provides agile consulting services in North America, Europe, and the Asia Pacific. The company offers finance and accounting services, including process transformation and optimization, financial reporting and analysis, technical and operational accounting, merger and acquisition due diligence and integration, audit readiness, preparation and response, implementation of new accounting standards, and remediation support. It also provides information management services, such as program and project management, business and technology integration, data strategy, and business performance management. In addition, the company offers corporate advisory, strategic communications, and restructuring services; and corporate governance, risk, and compliance management services, such as contract and regulatory compliance, enterprise risk management, internal controls management, and operation and information technology (IT) audits. Further, it provides supply chain management services comprising strategy development, procurement and supplier management, logistics and materials management, supply chain planning and forecasting, and unique device identification compliance; and human capital services, including change management, organization development and effectiveness, compensation and incentive plan strategies, and optimization of human resources technology and operations. Additionally, the company offers legal and regulatory supporting services for commercial transactions, global compliance initiatives, law department operations, and law department business strategies and analytics. It also provides policyIQ, a proprietary cloud-based governance, risk, and compliance software application. The company was formerly known as RC Transaction Corp. and changed its name to Resources Connection, Inc. in August 2000. Resources Connection, Inc. was founded in 1996 and is headquartered in Irvine, California.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. While the operating environment remained challenged in 1Q25 as clients continued to delay projects, RGP made strides in evolving its business model and rebuilding its brand architecture and positioning. A full recovery should follow improving client sentiment about the economy, but the Company is seeing pockets of improvement.

1Q25 Results. Revenue came in at $136.9 million, a decline of 19.5% y-o-y, but in-line with guidance. Gross margin was 36.5%, down from 39.4% a year ago and below management’s 37.5%-38.5% guide due to lower consultant utilization and unfavorable leverage on indirect costs. RGP recorded a $3.4 million gain on a sale as well as a $3.9 million impairment charge. Net loss for the quarter was $5.7 million, or a loss of $0.17/sh, compared to net income of $3.1 million, or EPS of $0.09/sh last year. Adjusted EPS was breakeven versus EPS of $0.20/sh in 1Q24.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

U.S. Indexes Fall as Iran Fires Missiles at Israel; Defense Stocks Surge

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– U.S. stock indexes drop, with Nasdaq down over 1% after Iran’s missile attack on Israel.
– Defense stocks rise as oil prices surge amid geopolitical tensions.
– Investors grow cautious, monitoring U.S. job data and port strikes.

U.S. stock markets took a sharp turn downward on Tuesday as news broke of Iran launching a barrage of ballistic missiles at Israel, heightening tensions in the Middle East. The Nasdaq Composite led the decline, falling by over 1%, while the broader market also saw losses, reflecting growing investor caution in the face of geopolitical instability. The Dow Jones Industrial Average fell by 0.2%, and the S&P 500 dropped 0.75%.

The attack by Iran is seen as retaliation for Israel’s ongoing military campaign against Hezbollah, Iran’s ally in the region. In response to the missile strikes, President Joe Biden directed the U.S. military to support Israel’s defense and to shoot down any missiles aimed at the country, as confirmed by the White House National Security Council.

While the broader market felt the impact of the escalating conflict, shares in the defense sector surged. Companies like Northrop Grumman and Lockheed Martin saw their stock prices rise, as investors shifted focus to the increased demand for defense and military technology in light of the conflict. The S&P 500 Aerospace and Defense Index rose by more than 1%, hitting a new record high.

Energy companies also benefitted from the geopolitical unrest, with oil prices rising alongside the tensions. Exxon Mobil gained 2.2% as West Texas Intermediate crude oil climbed over 4%. The possibility of further supply disruptions in the Middle East, which produces a significant portion of the world’s oil, pushed investors into energy stocks, which historically serve as a hedge during times of geopolitical uncertainty.

On the other hand, airline stocks like Delta Air Lines experienced losses, reflecting concerns over potential disruptions in travel and higher fuel costs. Delta’s shares dropped by 1%, as investors anticipated a tightening of air travel conditions due to escalating tensions in the region.

“This situation highlights the variety of risks the market is currently facing, from slowing employment to geopolitical tensions,” noted Walter Todd, Chief Investment Officer at Greenwood Capital. “The market is vulnerable to shocks like this, and it’s reacting accordingly.”

The heightened geopolitical risk comes at a time when U.S. markets were already grappling with several economic uncertainties. On Monday, the three major indexes had posted strong gains for September and for the third quarter, but Tuesday’s developments prompted a reversal of that trend. In addition to the conflict in the Middle East, investors are also closely watching economic data related to U.S. job openings and manufacturing activity, which rebounded in August but still signaled broader concerns about the health of the economy.

Increased market volatility followed the news, with the CBOE Volatility Index, also known as the VIX or “fear gauge,” jumping by two points to 18.74. Earlier in the session, the index had reached a three-week high of 20.73, indicating a growing sense of uncertainty among investors.

Meanwhile, the looming East Coast and Gulf Coast port strikes, which began Tuesday, added another layer of complexity to the market’s reaction. The strike has halted approximately half of the nation’s ocean shipping, potentially exacerbating economic disruptions and creating further uncertainty for policymakers at the Federal Reserve as they assess the state of the economy.

Investors will be watching closely as more economic data is released later in the week, particularly the U.S. jobless claims report on Thursday and the monthly payrolls data on Friday. With market sentiment already rattled by geopolitical events, these figures could further influence the outlook for future Federal Reserve interest rate cuts.

Looming U.S. East Coast Port Strike Threatens to Disrupt Shipping and Transportation Stocks

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– U.S. East Coast port workers are poised to strike, potentially halting container traffic from Maine to Texas.
– The strike could cost the U.S. economy an estimated $5 billion a day, directly impacting shipping and transportation stocks.
– Companies in logistics, shipping, and transportation sectors could face stock volatility due to supply chain disruptions.

In what could become the largest port disruption in decades, U.S. East and Gulf Coast port workers are set to strike, posing a significant threat to the nation’s economy and potentially shaking up transportation and shipping stocks. The International Longshoremen’s Association (ILA), representing 45,000 workers, has not reached an agreement with the United States Maritime Alliance (USMX), and with no talks scheduled, a strike appears imminent. The last coast-wide ILA strike was in 1977, and this impending strike could have far-reaching consequences.

This labor dispute could cost the U.S. economy as much as $5 billion per day, halting the flow of goods in and out of the nation’s busiest ports, from Maine to Texas. As retail businesses prepare for the holiday season, the strike threatens to create major supply chain bottlenecks, increasing the pressure on companies that depend on timely shipping and logistics to meet demand.

For transportation and shipping stocks, the impact could be immediate. Stocks of companies like FedEx, UPS, XPO Logistics, and JB Hunt Transport Services could see increased volatility as the strike unfolds. Container shipping companies such as Matson, ZIM Integrated Shipping Services, and Danaos Corporation are also likely to face challenges due to disruptions in port activity. With nearly 100,000 containers expected to be stuck at the ports of New York and New Jersey alone, delays in deliveries could result in higher costs, slower operations, and potentially reduced earnings for logistics and transportation companies.

The strike could also have a ripple effect across transportation stocks beyond just those involved in logistics. Companies in industries dependent on port activity, such as retailers, manufacturers, and automotive suppliers, may see disruptions in their supply chains. This could create downward pressure on stock prices across a variety of sectors, further compounding the economic damage.

The broader shipping sector is also vulnerable to sudden shifts in stock value, particularly if delays cause shipping costs to rise. Companies with heavy exposure to East Coast and Gulf Coast ports may face increased operational costs as they are forced to reroute goods through alternative ports or transport modes, impacting their bottom line. Analysts are watching shipping stocks closely, and any prolonged strike could lead to earnings downgrades for several transportation companies.

As the labor dispute remains unresolved, investors in transportation and shipping stocks will need to monitor developments closely. Prolonged disruptions could have a significant effect on quarterly earnings, stock performance, and overall sector sentiment. With no negotiations planned, the situation is on a knife’s edge, and any news about progress—or the lack thereof—will likely trigger swift movements in related stocks.

Take a moment to take a look at emerging growth companies EuroDry Ltd. and EuroSeas Ltd.

Release – V2X Awarded Position On $11.9 Billion JETS 2.0 Contract To Deliver Cybersecurity Solutions

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on VVX

MCLEAN, Va., Oct. 1, 2024 /PRNewswire/ — V2X, Inc. (NYSE: VVX) announces its selection for the $11.9 billion Defense Logistics Agency (DLA) J6 Enterprise Technology Services 2.0 (JETS 2.0) contract, securing its place amongst a select group of providers.

“In today’s rapidly evolving digital landscape, vigilance is paramount. V2X is proud to support the Defense Logistics Agency by delivering critical cybersecurity and IT modernization services to uphold their mission,” said Jeremy C. Wensinger, President and Chief Executive Officer of V2X.

Under the JETS 2.0 contract, V2X will provide a range of advanced IT solutions, including cloud services and cybersecurity services to the DLA. This indefinite-delivery/indefinite-quantity contract spans an initial five-year base period, with the potential for an additional five-year option, supporting both U.S. and international Defense Department operations with essential IT services.  

About V2X

V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Media Contact 
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

Investor Contact 
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-awarded-position-on-11-9-billion-jets-2-0-contract-to-deliver-cybersecurity-solutions-302264119.html

SOURCE V2X, Inc.

Release – SES Space and Defense Awards Comtech Order for Next-generation Modems to Operate on O3b mPOWER Constellation

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on CMTL

CHANDLER, Ariz. – Oct. 1, 2024– Comtech (NASDAQ: CMTL) (the “Company”), a global technology leader, today announced SES Space & Defense recently awarded the Company an initial order for Comtech’s market-leading software-defined SLM-5650B and other next-generation modems. Initial quantities under this new contract are expected to be delivered over the next year.

“In today’s threat environment, secure, resilient, and ubiquitous connectivity is critical to maintaining an information advantage across all domains,” said John Ratigan, Interim CEO of Comtech. “This contract award further demonstrates the trust of SES Space & Defense in Comtech’s ability to deliver next-generation digital solutions. O3b mPOWER is among the world’s most innovative satellite constellations, and we are thrilled to partner with SES Space & Defense as they pave the way for modernized military satellite communications (“SATCOM”) operations.”

“We choose customer mission success first. Comtech’s SLM modem series includes features that are unique and critical to our customers’ missions,” said David Fields, President and CEO of SES Space & Defense. “It is important that Comtech is part of the O3b mPOWER service infrastructure. Their experience developing and manufacturing defense-oriented modems that are ‘allied by design’ with footprints in many domestic and international programs of records make it an easy decision.”

Developed and manufactured at its headquarters in Chandler, AZ, Comtech’s SLM-5650B is the Company’s current Wideband Global SATCOM-certified modem designed to deliver critical communications services for commercial backhaul and government and military applications. The software-defined SLM-5650B currently supports multiple critical DoD and NATO waveforms including DVB-S2X, the preferred waveform for SES’ O3b mPOWER constellation, with the ability to easily add more waveforms and functions to meet emerging mission needs.

Comtech’s portfolio of U.S. sovereign defense technologies and services, including the Company’s SLM-5650B and next-generation modems, align with the Space Force Commercial Space Strategy and deliver capabilities that will enhance Combined Joint All Domain Command and Control operations. Comtech’s expansive portfolio of defense and security technologies is designed to continuously evolve over time to enable digitalized SATCOM infrastructures and integrate services across blended military and commercial networks to significantly enhance mission effectiveness in future all-domain operations.

About Comtech

Comtech Telecommunications Corp. is a leading global technology company providing terrestrial and wireless network solutions, next-generation 9-1-1 emergency services, satellite and space communications technologies, and cloud native capabilities to commercial and government customers around the world. Our unique culture of innovation and employee empowerment unleashes a relentless passion for customer success. With multiple facilities located in technology corridors throughout the United States and around the world, Comtech leverages our global presence, technology leadership, and decades of experience to create the world’s most innovative communications solutions.For more information, please visit www.comtech.com.

About SES Space & Defense

SES Space & Defense is a wholly-owned subsidiary of SES and is exclusively focused on building, managing, and supporting the most advanced satellite network solutions for the U.S. Government. SES Space & Defense uses a proven multi-operator network integration and management capability, a broad global terrestrial network, as well as access to SES’s multi-orbit satellite fleet. It also offers U.S. Department of Defense customers the essential tools in cybersecurity for mission-critical operations, coupled with a proven track record in governance and compliance. SES Space & Defense operates under a proxy board, enabling it to support classified projects, and it has participated in the U.S. Government satcom sector for nearly five decades. Further information can be found at: www.sessd.com.

Forward-Looking Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results and performance could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

PCMTL

Investor Relations Comtech

Maria Ceriello

631-962-7115

Maria.Ceriello@comtech.com

Media Contact Comtech

Jamie Clegg

480-532-2523

jamie.clegg@comtech.com

Media Contact SES Space & Defense

Melanie Delannoy

Tel. +1 571 443 7993

melanie.delannoy@sessd.com

Traws Pharma (TRAW) – Phase 1 Ratutrelvir Results Announced With Plans To Move To Phase 2a

Posted on by cpereira@noblefcm.com


Tuesday, October 01, 2024

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in a combination trial with estrogen blockade in advanced endometrial cancer. Based on preclinical and clinical studies of CDK 4/6 inhibitors, Onconova is also evaluating opportunities for combination studies with narazaciclib in additional indications. Onconova’s product candidate rigosertib is being studied in multiple investigator-sponsored studies. These studies include a dose-escalation and expansion Phase 1/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer, a Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC), and a Phase 2 trial evaluating rigosertib in combination with pembrolizumab in patients with metastatic melanoma.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 1 Topline Data Shows Safety and Tolerability. Traws Pharma announced results from its Phase 1 trial testing ratutrelvir, its oral protease inhibitor for COVID-19. The trial was designed to determine pharmacokinetics and safety, with results showing consistent plasma levels within the expected range with no adverse events. A Phase 2a trial is being planned to begin in 1H2025.

Ratutrelvir Could Become A Category-Leading Drug. Ratutrelvir is an inhibitor of the SARS-CoV-2 Main protease (Mpro or 3CL protease). It has demonstrated in vitro activity against the original viral strain and numerous variants, including delta and omicron. Ratutrelvir does not require co-administration of ritonavir as a metabolic inhibitor and avoids the drug-drug interactions and potential side effects. In comparison, Pfizer’s Paxlovid is a combination of its Mpro inhibitor, nirmatrelvir, with ritonavir as a metabolic (cytochrome P450) inhibitor.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.